4/A: Linda A. Fitzpatrick Corrects Form 4 Filing for Sutro Biopharma, Inc.

Linda A. Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, Inc., amends a previous Form 4 filing to correct the number of restricted stock units (RSUs) granted on March 5, 2024.

Summary

• Linda A. Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the number of restricted stock units (RSUs) granted to Fitzpatrick on March 5, 2024.
• The corrected filing shows that Fitzpatrick was granted 37,100 RSUs on March 5, 2024.
• These RSUs vest in equal annual installments beginning on March 1, 2025, contingent upon continued service.
• Each RSU represents the right to receive one share of Sutro Biopharma's common stock upon settlement.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing. The correction of the RSU number is a neutral event, but the grant itself suggests continued investment in key personnel.

Future Outlook

The RSUs vest annually beginning March 1, 2025, subject to continued service, indicating a long-term incentive for the reporting person.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider ownership.
• The RSU grant incentivizes the Chief People & Communications Officer, potentially benefiting employees and the company's overall performance.

Key Dates